CSTLCastle Biosciences Inc

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire FRIENDSWOOD, Texas, July 9, 2026 FRIENDSWOOD, Texas, July 9...

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire FRIENDSWOOD, Texas, June 25...

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire FRIENDSWOOD, Texas, June 23, 2026 Stokes was...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire FRIENDSWOOD, Texas, June 19, 2026 FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq...

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire...

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics...

Castle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analysts...

Castle Biosciences (NASDAQ:CSTL) reported first-quarter 2026 revenue of $83.7 million, supported by continued growth in what management described as its "core revenue drivers," DecisionDx-Melanoma and TissueCypher. Founder, President and CEO Derek Maetzold said test report volumes for the company's...

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?